CD11c⁺ myeloid cell exosomes reduce intestinal inflammation during colitis

Kaylyn M. Bauer,¹ Morgan C. Nelson,¹ William W. Tang,¹ Tyson R. Chiaro,¹ D. Garrett Brown,¹ Arevik Ghazaryan,¹ Soh-Hyun Lee,¹ Allison M. Weis,¹ Jennifer H. Hill,¹ Kendra A. Klag,¹ Van B. Tran,¹ Jacob W. Thompson,¹ Andrew G. Ramstead,¹ Josh K. Monts,² James E. Marvin,² Margaret Alexander,¹ Warren P. Voth,¹ W. Zac Stephens,¹ Diane M. Ward,¹ Aaron C. Petrey,¹,³ June L. Round,¹,⁴ and Ryan M. O’Connell¹,⁴

¹Department of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, Utah, USA. ²University of Utah Flow Cytometry Core, Salt Lake City, Utah, USA. ³Department of Internal Medicine, Division of Gastroenterology, and Hunstman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

Intercellular communication is critical for homeostasis in mammalian systems, including the gastrointestinal (GI) tract. Exosomes are nanoscale lipid extracellular vesicles that mediate communication between many cell types. Notably, the roles of immune cell exosomes in regulating GI homeostasis and inflammation are largely uncharacterized. By generating mouse strains deficient in cell-specific exosome production, we demonstrate deletion of the small GTPase Rab27A in CD11c⁺ cells exacerbated murine colitis, which was reversible through administration of DC-derived exosomes. Profiling RNAs within colon exosomes revealed a distinct subset of miRNAs carried by colon- and DC-derived exosomes. Among anti-inflammatory exosomal miRNAs, miR-146a was transferred from gut immune cells to myeloid and T cells through a Rab27-dependent mechanism, targeting Traf6, IRAK-1, and NLRP3 in macrophages. Further, we have identified a potentially novel mode of exosome-mediated DC and macrophage crosstalk that is capable of skewing gut macrophages toward an antiinflammatory phenotype. Assessing clinical samples, RAB27A, select miRNAs, and RNA-binding proteins that load exosomal miRNAs were dysregulated in ulcerative colitis patient samples, consistent with our preclinical mouse model findings. Together, our work reveals an exosome-mediated regulatory mechanism underlying gut inflammation and paves the way for potential use of miRNA-containing exosomes as a novel therapeutic for inflammatory bowel disease.

Introduction

The gastrointestinal (GI) tract harbors a complex immune system that is in constant communication with many cell types and organ systems and that underlies many facets of human health. Maintenance of the GI tract is specifically dependent on proper signaling between the GI immune system and intestinal epithelial cells (IECs). Communication between these cell types is necessary for immune tolerance to commensal microbes, intestinal barrier maintenance, and appropriate responses to pathogenic organisms (1, 2). While our understanding of the immunological mechanisms dictating intestinal homeostasis and the progression of inflammatory diseases in the gut has been under intense investigation in recent decades, many questions regarding the roles of host intercellular signaling remain.

Host extracellular vesicles (EVs) are an important mode of intercellular communication with immunoregulatory properties, yet their functions within the GI tract during health and disease remain largely unclear. IECs, mesenchymal stem cells, and hematopoietic cells all secrete EVs, and populations of these heterogeneous vesicles are readily found in bodily fluids (3, 4). Importantly, distinct EV populations with more immunomodulatory potential were detected in the luminal aspirates of both healthy pediatric and adult controls compared to inflammatory bowel disease (IBD) patients, highlighting their potential importance to disease (5, 6). Although immune populations and their functions change along the length of the human and mouse GI tracts, it is unknown whether EVs from distinct regions or from distinct immune cells or other sources possess different roles in response to intestinal barrier challenges (7, 8). It has also been known that specialized IEC-derived vesicles, termed “tolerosomes,” display...
MHCII with bound antigen and can travel to lymph nodes and induce tolerance to an orally fed antigen (9–11). Further, exosomes released from apical versus basolateral surfaces of murine IECs differ in their protein composition, suggesting a specialized function for EVs based on the cell of origin or release mechanism (3). However, the identity, contents, and functions of EVs produced by distinct immune cell types within the GI tract remain undefined.

Exosomes, a subset of EVs, are 50 to 200 nm lipid vesicles derived from the multi-vesicular body (MVB) pathway and contain myriad bioactive molecules, including miRNAs (12). miRNAs are small noncoding RNAs that regulate target messenger RNAs by binding their 3′ UTRs to repress translation or reduce stability (13, 14). miRNAs are known to be critical for proper intestinal homeostasis (15, 16). Vesicular trafficking allows for protected intercellular miRNA transfer to regulate target genes in recipient cells, ranging from neighboring cells to those in distal organs (17, 18). The highly stable nature of these vesicular miRNAs makes them appealing as a cell-free therapeutic (19); however, the in vivo functional roles of vesicular miRNAs within the GI tract remains largely uncharacterized.

A particular subset of exosomes is released through a mechanism involving RAB27A and RAB27B, 2 widely expressed small GTPases in the secretory pathway (20–23). RAB27A and RAB27B are functionally redundant in some cell types but are also distinct in other contexts (24–26). With regard to exosome secretion, it is thought that RAB27A is responsible for docking the exosome-containing MVB at the plasma membrane, while RAB27B aids in transferring the MVB from microtubules (23). The dual loss of murine RAB27A and RAB27B results in a chronic inflammatory state and decreased responsiveness to LPS challenge (27), along with defective Treg function (28). Loss of human RAB27A function results in Griscelli syndrome (GS) type 2, wherein patients have a defective immune system and increased risk of viral infection, often requiring BM transplantation in childhood (29). Altered immune cell expression of RAB27A and RAB27B was reported for a cohort of ulcerative colitis (UC) colon biopsy samples, although their functions in this setting was unclear (30). Although it is established that RAB27A/B contribute to exosome release and immune modulation, the individual roles of these GTPases in distinct exosome-producing cell types in vivo as well as their specific functions in the GI tract have been generally unexplored.

Here, we report that whole-body Rab27a and Rab27b double-KO (Rab27DKO) mice have reduced exosome secretion from colonic tissue. However, we also found that the cellular expression patterns of these 2 genes were largely nonoverlapping. Consequently, we created conditional KO mice for either RAB27A or RAB27B in hematopoietic cells and IECs to examine their specific contributions to GI immune regulation. Using 2 distinct preclinical models of UC, we found increased disease severity in mice lacking RAB27A specifically in hematopoietic or CD11c+ myeloid cells. We then found that DC-derived EVs rescued exacerbated colitis in hematopoietic Rab27a-deficient mice. Small RNAs in colon explant– and DC-derived exosomes were profiled to identify exosomal miRNAs potentially responsible for reducing colitis in our mouse model. We found that miR-146a, along with a subset of other antiinflammatory miRNAs, were enriched in DC and colonic exosomes and that exosome-mediated miR-146a transfer between immune cells within the gut was largely RAB27A dependent. Further, we identified an exosome-dependent mechanism of GI macrophage skewing mediated through uptake of DC-derived exosomal miR-146a, a known antiinflammatory miRNA that targets TNF receptor associated factor 6 (TRAF6), interleukin 1 receptor associated kinase 1 (IRAK-1), and NLR family pyrin domain containing 3 (NLRP3), key proinflammatory regulators. Finally, we extended our studies to clinical samples, where we observed dysregulated expression of RAB27A, RNA-binding proteins that can load miRNAs in exosomes, and miRNAs in colon tissues from patients with UC but not Crohn’s disease (CD).

Results
RAB27DKO mice display reduced colonic exosome secretion. Little is known regarding how exosomes influence intestinal health; therefore, we profiled immune parameters within steady-state colons of Rab27DKO and WT animals. To verify decreased exosome release within the gut, as seen in other cellular compartments of these animals, vesicles were isolated from colonic explants of WT and Rab27DKO mice by differential centrifugation, and their size profiles and concentration were determined using nanoparticle tracking analysis (NTA) (Figure 1A). After quantifying particles in the defined exosome range (50–200 nm) (Figure 1B), and examining known exosome tetraspanin markers (CD63 and CD9) by Western blotting (Figure 1C), we found decreased exosome secretion from the colon of Rab27DKO mice versus controls.
Next, we measured the expression of both GTPases in murine small intestine (SI), colon, and spleen tissues by quantitative PCR (qPCR) to define their expression profiles. Both Rab27a and Rab27b were highly expressed in the SI and colon, whereas only Rab27a was clearly detected in the spleen (Figure 1, D and E), consistent with previous reports of RAB27A and RAB27B protein expression (20). Further, we found that Rab27a was expressed in CD4+, CD8+, and B220+ populations sorted from the spleen, while Rab27b was not detected (Figure 1F, unpublished observations). Mining available murine SI single-cell RNA-sequencing (scRNA-Seq) data sets, we found that Rab27a has a diverse expression profile in the hematopoietic compartment of the SI, with detectable expression across many distinct cellular lineages (Figure 1G) (31). Rab27b has a more restricted expression profile, with the highest expression limited to the epithelial cluster (Figure 1G). Since both GTPases are expressed in epithelial cells and highly expressed in whole SI and colon tissues, we assessed scRNA-Seq of the murine SI epithelial cell compartment (32).

Again, there was a distinct epithelial cell profile, with both Rab27a and Rab27b being most highly expressed in the tuft, goblet, and enteroendocrine cell clusters versus the other clusters (Figure 1H). This distinct expression of Rab27a and Rab27b across the intestinal landscape led us to create cell type–specific conditional KO mice to further investigate the individual roles of these 2 GTPases in gut exosome secretion and in regulating intestinal homeostasis and inflammatory responses.

Rab27a in the hematopoietic compartment modulates inflammatory responses in the GI tract. Utilizing CRISPR-based approaches, we generated floxed mouse strains targeting Rab27a and Rab27b. For Rab27a, we targeted exon 4 (transcript variant 1), the location of some of the natural point mutations in GS type 2, and confirmed by Southern blot that founder floxed-only mice had correct insertions of loxP sites (29, 33) (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.159469DS1). For Rab27b, we targeted exons 3 to 4 (transcript variant 2), predicted to result in a nonfunctional protein after deletion, and again confirmed loxP insertions by Southern blot (Supplemental Figure 1, C and D). We generated broad hematopoietic cell KO animals for either Rab27a or Rab27b by crossing these floxed mice with Vav-iCre mice. Next, we challenged both strains with dextran sulfate sodium (DSS) to induce acute colitis. Results indicate that Vav-iCre Rab27a/fl/fl animals were more susceptible to DSS-induced weight loss and colon shortening, indicating worsened disease than floxed littermate controls. This suggests a role for hematopoietic cell–derived exosomes in maintaining inflammation (Figure 2, A and B). The use of littermate controls aided us in controlling for microbiota differences between the groups for this experiment and subsequent experiments by exposing all pups to the same initial microbiota. In contrast to the Vav-Rab27a cKO, Vav-iCre Rab27b/fl/fl (Vav-Rab27b cKO) mice did not show a change in weight or colon length compared to littermate controls during colitis experiments (Figure 2, C and D).

Due to the detection of Rab27a and Rab27b in IECs by scRNA-Seq and qPCR, we investigated the contribution of epithelial cell–derived Rab27a and Rab27b to the maintenance of the intestinal barrier and response to inflammatory challenge. Floxed animals were crossed with Villin1-Cre mice and subjected to DSS-induced colitis. We found that knocking out either Rab27a or Rab27b in the IECs did not affect DSS-induced colitis weight loss (Figure 2, E–H). Villin-Cre Rab27a/fl/fl animals had modestly longer colons after challenge, potentially indicating some resistance to colitis challenge (Figure 2F). Villin-Cre Rab27b/fl/fl animals displayed no change in colon length, indicating that Rab27b within the IEC compartment is not modulating this particular response (Figure 2H). Collectively, these results indicate a critical role for hematopoietic derived Rab27a in limiting disease during DSS-induced colitis.

Next, we further characterized the colons of Vav-Rab27a cKO mice after DSS colitis. By H&E staining, we observed a higher incidence of crypt loss, worsened crypt destruction, and increased inflammation versus WT controls. This resulted in an elevated total histology score, indicating increased disease severity (Figure 2, I–L). Representative images of this pathology are shown (Figure 2M). Additionally, we measured serum lipocalin-2 (LCN2) levels, which correspond with disease state, and found higher LCN2 in Vav-Rab27a cKO animals versus WT controls (Figure 2N). To determine the relevant immune cell type(s) responsible for exacerbating colitis within Vav-Rab27a cKO animals, we examined the immune cells present during colitis in Vav-Rab27a cKO mice compared with floxed controls. There was an increased proportion of CD38+ “M1-like” macrophages and elevated Th17 cells in the colonic lamina propria (cLP) of Vav-Rab27a cKO mice after DSS colitis (Figure 2, O and P). Proper Rab27a deletion in Vav-Rab27a cKOs was validated by qPCR, by Western blot, and by a subsequent decrease in hematopoietic exosome secretion measured by NTA (Supplemental Figure 2, A–C).
Because a colitis phenotype associated with Villin-Cre Rab27a/b deletion was not observed, we wanted to confirm that all other Rab27 cKOs were functioning as expected. Using Western blots and qPCR, we confirmed deletion of RAB27A or RAB27B with Villin1-Cre (Supplemental Figure 2, D–G). Additionally, Rab27b was not upregulated upon loss of Rab27a in immune cells, suggesting no functional compensation between the conditions analyzed (unpublished observations). Further, other Rab GTPases (Rab2b, Rab5a, and Rab9a) were not upregulated despite being potentially involved in exosome secretion in HeLa cells (23). This highlights Rab27a’s importance to this process of suppressing inflammation in the gut during colitis. We also did not observe any obvious changes to baseline phenotypes in the guts of any of these.
mice as indicated by no changes to the colon lengths of these Rab27 cKOs versus floxed controls (Supplemental Figure 2H) as well as no significant alterations to pertinent immune cell populations in the thymus, mesenteric lymph node (mLN), spleen, or cLP at baseline (unpublished observations). Importantly, there were also no changes to macrophage populations, as defined by CD38 and early growth response 2 (Egr2) markers, at steady-state between floxed and cKO animals (Supplemental Figure 2I).

Having observed a critical role for hematopoietic RAB27A during DSS-induced colitis, we wanted to confirm that this phenomenon occurred in a second model of colitis. To do this, we utilized the anti–IL-10 receptor (αIL-10R) blocking mAb model of IBD (34). This model is akin to the IL-10−/− model of spontaneous colitis but occurs more frequently and at a quicker pace than the KO animal model (35). Four weekly i.p. injections of αIL-10R mAbs were administered (Figure 2Q). We found that Vav-Rab27A cKO mice had increased weight loss and shorter colon lengths compared with floxed controls that also received the mAb (Figure 2, Q and R). No differences between the 2 groups were observed upon vehicle administration alone (Supplemental Figure 2J). Additionally, histological analysis indicated that Vav-Rab27A cKO had a greater occurrence of epithelial hyperplasia, goblet cell loss, and inflammatory aggregates as reflected in the total histology score, which is common for this model of colitis (Figure 2, S and T) (36, 37). Representative images of the mAb colons and quantification of the inflammatory aggregates are shown (Supplemental Figure 2K). Finally, we observed a similar shift in macrophage populations in Vav-Rab27A cKO mouse colons similar to DSS colitis, with more “M1-like” macrophages compared with “M2-like” macrophages (Figure 2U). Cumulatively, these results indicate that hematopoietic RAB27A function is crucial for regulating the inflammatory response during IBD.

Rab27a functions in myeloid cells to release exosomes that suppress DSS-induced colitis. Previous in vitro literature indicates an immune-regulatory role for DC- and T cell–derived EVs, and our observed alterations of the myeloid and T cell compartments in Vav-Rab27a cKO mice during intestinal inflammation prompted us to generate more specific cKO animals to identify relevant immune cell types involved in worsened colitis in the absence of hematopoietic Rab27a. Rab27a−/− mice were crossed with CD11c-Cre and CD4-Cre mouse strains to examine the relative contributions of Rab27a within the innate and adaptive arms of immunity. Decreased Rab27a/RAB27A expression were confirmed via qPCR and Western blot in both cKO animals (Supplemental Figure 3, A and B). While CD4-Cre Rab27a−/− mice displayed no difference compared to controls during DSS colitis or at baseline (Supplemental Figure 3C), CD11c-Cre Rab27a−/− animals (CD11c-Rab27a cKO) exhibited greater weight loss and colonic shortening following DSS treatment, indicating that myeloid cells, including DCs and some macrophages, within the hematopoietic compartment utilize RAB27A to restrict DSS colitis phenotypes (Figure 3, A–D).

Profiling of CD11c-Rab27a cKO animals demonstrated altered macrophage populations that included increased levels of CD11c “M1-like” proinflammatory CD38+ macrophages and decreased CD11c Egr2+ “M2-like” antiinflammatory macrophages, compared with floxed littermate controls in the mLNs and cLP (Figure 3, E–G). Elevated serum LCN2 levels and increased epithelial damage, as shown in representative images, were observed in CD11c-Rab27a cKO mice versus controls, consistent with worsened disease (Figure 3, H–J). No significant alterations to the macrophage populations within the homeostatic colons of CD11c-Rab27a cKO were observed, nor were any alterations to colon length, spleen weight, or fecal LCN2 levels (Supplemental Figure 3, D–F). We also assessed the response of these CD11c-Rab27a cKO and floxed mice to the αIL-10R mAb model of IBD and saw a phenocopy of the histological changes seen in Vav-Rab27a cKO mice challenged with this same model (Figure 3, K and L), including increased epithelial crypt depth and total number of inflammatory aggregates in Vav-Rab27A cKO mice (Figure 3M). These data suggest a critical role for Rab27a-dependent, DC-derived exosomes within the intestinal microenvironment during experimental IBD, leading us to examine the molecular cargo carried and delivered by these EVs that could be responsible for this antiinflammatory function of RAB27A within the GI tract.

DC-derived exosomes containing miRNAs are released in the intestinal microenvironment. Exosomes are composed of many bioactive molecules, including miRNAs, which are one of the most abundant EV noncoding RNA species (38, 39). Because miRNAs are critical regulators of inflammation and colitis, we examined gut-derived EVs to determine which miRNAs they carry that may have regulatory functions during colitis. Because we saw defects in inflammation control when DCs could not release exosomes, we compared colon EV miRNAs to BM-derived DC (BMDC) EV miRNAs to determine which miRNAs were present in both BMDCs and in a highly heterogeneous colon explant EV preparation. To do this, exosomes were purified from BMDCs or colon explants with an iodixanol gradient, followed by miRNA sequencing (Figure 4A). Thirty-two miRNAs were enriched in colon EVs compared with BMDC EVs, 20 were enriched in BMDC EVs, and 15 were common for this model of colitis (Figure 2, S and T) (36, 37). Representative images of the mAb colons and quantification of the inflammatory aggregates are shown (Supplemental Figure 2K). Finally, we observed a similar shift in macrophage populations in Vav-Rab27A cKO mouse colons similar to DSS colitis, with more “M1-like” macrophages compared with “M2-like” macrophages (Figure 2U). Cumulatively, these results indicate that hematopoietic RAB27A function is crucial for regulating the inflammatory response during IBD.

DC-derived exosomes containing miRNAs are released in the intestinal microenvironment. Exosomes are composed of many bioactive molecules, including miRNAs, which are one of the most abundant EV noncoding RNA species (38, 39). Because miRNAs are critical regulators of inflammation and colitis, we examined gut-derived EVs to determine which miRNAs they carry that may have regulatory functions during colitis. Because we saw defects in inflammation control when DCs could not release exosomes, we compared colon EV miRNAs to BM-derived DC (BMDC) EV miRNAs to determine which miRNAs were present in both BMDCs and in a highly heterogeneous colon explant EV preparation. To do this, exosomes were purified from BMDCs or colon explants with an iodixanol gradient, followed by miRNA sequencing (Figure 4A). Thirty-two miRNAs were enriched in colon EVs compared with BMDC EVs, 20 were enriched in BMDC EVs, and 15 were common for this model of colitis (Figure 2, S and T) (36, 37). Representative images of the mAb colons and quantification of the inflammatory aggregates are shown (Supplemental Figure 2K). Finally, we observed a similar shift in macrophage populations in Vav-Rab27A cKO mouse colons similar to DSS colitis, with more “M1-like” macrophages compared with “M2-like” macrophages (Figure 2U). Cumulatively, these results indicate that hematopoietic RAB27A function is crucial for regulating the inflammatory response during IBD.

DC-derived exosomes containing miRNAs are released in the intestinal microenvironment. Exosomes are composed of many bioactive molecules, including miRNAs, which are one of the most abundant EV noncoding RNA species (38, 39). Because miRNAs are critical regulators of inflammation and colitis, we examined gut-derived EVs to determine which miRNAs they carry that may have regulatory functions during colitis. Because we saw defects in inflammation control when DCs could not release exosomes, we compared colon EV miRNAs to BM-derived DC (BMDC) EV miRNAs to determine which miRNAs were present in both BMDCs and in a highly heterogeneous colon explant EV preparation. To do this, exosomes were purified from BMDCs or colon explants with an iodixanol gradient, followed by miRNA sequencing (Figure 4A). Thirty-two miRNAs were enriched in colon EVs compared with BMDC EVs, 20 were enriched in BMDC EVs, and 15 were common for this model of colitis (Figure 2, S and T) (36, 37). Representative images of the mAb colons and quantification of the inflammatory aggregates are shown (Supplemental Figure 2K). Finally, we observed a similar shift in macrophage populations in Vav-Rab27A cKO mouse colons similar to DSS colitis, with more “M1-like” macrophages compared with “M2-like” macrophages (Figure 2U). Cumulatively, these results indicate that hematopoietic RAB27A function is crucial for regulating the inflammatory response during IBD.
EVs compared with colon EVs, and 43 were roughly equivalent in exosomes from the 2 sources (Figure 4, B and C; NCBI Gene Expression Omnibus [GEO] accession: GSE190854). We verified the presence of 3 miRNAs from our sequencing, miR-146a, miR-155, and Let-7d, within SI and colon explant exosome preparations by qPCR, highlighting their potential importance in the gut (Figure 4, D and E).

Next, we repurposed a murine model to track the cellular source of colonic exosomal miRNAs. We developed several types of mTmG reporter mice by crossing mTmG mice with Villin1-Cre, Vav-iCre, and CD11c-Cre to produce mouse strains with cell-specific plasma membrane GFP-labeled exosomes. With this system, GFP+ vesicles originate from Cre+ cells that have recombined the lox-mTomato-stop-lox system upstream from N-terminus membrane tagged GFP within the Rosa locus of these mice (40). The default fluorescence of Cre+ cell plasma membranes is mTomato, while Cre+ cells label their membranes with GFP, including exosomal membranes. A large percentage of colon explant vesicles were derived from IECs, as expected. A substantial proportion of vesicles were also hematopoietic cell derived, while a small percentage of vesicles were from CD11c+ cells (Figure 4F). With this system, we were able to track the cellular sources of the miRNAs found in colon EV preparations. Using a FACS Aria II cell sorter (BD), GFP+ EVs were sorted from colon explants of either Villin1-Cre mTmG mice or Vav-iCre mTmG mice, and RNA was isolated from these exosomes (Figure 4G). Using qPCR, we assayed 3 anti-inflammatory miRNA candidates from our sequencing results that included miR-146a, miR-342-3p, and miR-223-3p, all of which are thought to regulate NF-kB (41–43). Each was demonstrated to be enriched in Vav-iCre mTmG GFP+ vesicles, consistent with hematopoietic, and potentially DC, origin (Figure 4, H–J). We also observed unchanged miR-141 between GFP+ vesicle populations from either Villin-Cre or Vav-iCre origin as a control (Figure 4J). Of note, we were unable to recover enough RNA from sorted CD11c+ cell–derived exosomes for downstream analysis by qPCR. Collectively, these results indicate that selected exosomal miRNAs originate from a hematopoietic source, which includes CD11c+ dendritic and other myeloid cells.

Rab27a-dependent transfer of exosomal miR-146a to gut macrophages and T cells in vivo. After detecting miR-146a at high levels in GFP+ colon EVs from Vav-iCre mTmG mice, and knowing its importance in the gut and overall immune regulation (41–43), we developed an in vivo system to detect possible Rab27-dependent miR-146a transfer and a way to determine recipient cell identity. We utilized BM chimeras, wherein miR-146a+/−CD45.2 irradiated animals were the recipients of miR-146a−/−CD45.2 BM, a 1:1 mix of WT CD45.1 and miR-146a−/−CD45.2 BM, or a 1:1 mix of Rab27DKO CD45.1 and miR-146a−/−CD45.2 BM (Figure 5A and Supplemental Figure 4A). After reconstitution, FACS was used to isolate miR-146a+/−CD45.2+ immune cell subsets from mLN s and cLP and qPCR used to detect transferred miR-146a after verifying BM reconstitution (Figure 5A). miR-146a was detected in miR-146a+/−CD45.2 CD11b+ myeloid and CD3+ T cells in both the mLN s and cLP, indicating Rab27-dependent transfer of miR-146a in vivo (Figure 5B).

With this intercellular transfer of miR-146a determined, we wanted to further demonstrate that GFP+ vesicle-like lipid puncta from CD11c-Cre mTmG mice were associated with CD11b+ and CD4+ cells within the mLN s (Figure 5C and Supplemental Figure 4B). Utilizing ImageStream technology, we observed these GFP+ puncta on CD3+CD11b+ and CD3+CD4+mTomato+ cells within the mLN s, indicating that lipids originating from CD11c+ cells were taken up by CD4+ T and CD11b+ myeloid cells (Figure 5, D and E). Importantly, we did not see any green vesicle-like puncta in CD11c-Cre mTmG0/0 control mLN samples (Supplemental Figure 4C). These data support the hypothesis that CD11c cell–derived vesicles, containing miR-146a, are delivered to myeloid and T cell populations within gut lymph nodes and intestinal tissues.
Figure 3. Rab27A functions in CD11c+ myeloid cells to regulate colitis phenotypes. (A) Weight loss of floxed animals versus CD11c-Cre Rab27A+ animals during a 6-day DSS course. (B) Colon length of A (n = 9), data representative of 4 independent experiments. (C) Weight loss of floxed versus CD4-Cre Rab27A+ animals during an 8-day DSS course (n = 9). (D) Colon length of C. (E) Representative flow plot of macrophage gating of F and G. (F) Percentage of CD38+ M1-like macrophages and of Erg2+ M2-like macrophages in floxed and CD11c-Rab27A cKO mLNs after DSS (n = 9). (G) Percentage of CD38+ M1-like macrophages and of Erg2+ M2-like macrophages in WT and CD11c-Rab27A cKO cLP after DSS (n = 6). (H) Serum LCN2 levels of mice from A as measured by ELISA (n = 6). (I) Percentage of colon crypt loss, severity of colon crypt loss, inflammation score, and total histology score of H&E-stained colons of A (n = 9). (J) Representative H&E-stained colons from A. (K) Representative H&E staining from WT and CD11c-Rab27A cKO mAb mice. (L) Total histology scores of K. (M) Quantification of epithelial crypt depth and number of inflammatory aggregates in K. Two-way ANOVA mixed model analysis with Geisser-Greenhouse correction for weight loss graphs. Unpaired 2-tailed t test for bar graphs except L. For L, 2-way ANOVA with Tukey’s multiple-comparison test comparing the column means. *P < 0.05, **P < 0.005, ***P < 0.0005. Scale bars in all images are 100 μm. See also Supplemental Figure 3.
Finally, to better understand the overall gut immune cell repertoire capable of receiving these vesicles, we utilized traditional flow cytometry to detect CD45<sup>+</sup>CD11c<sup>+</sup>mTomato<sup>+</sup> cells that were also membrane GFP<sup>+</sup> (mGFP<sup>+</sup>), consistent with receiving GFP lipid membranes from CD11c<sup>+</sup> DCs and macrophages. We examined both the mLNs and cLP of mTmG and CD11c-Cre<sup>+</sup> mTmG mice and saw distinct immune patterns based on anatomic location. Within the myeloid lineage in the mLNs, there was a preference for P3/4 monocytes, “M1-like” macrophages, and neutrophils to be mGFP<sup>+</sup> (Figure 5, E and F). Interestingly, this pattern shifted in the cLP to include more monocyte lineages, and there was less mGFP positivity in the neutrophil populations. Importantly, we also looked at the adaptive immune system and saw that within the mLNs, CD4<sup>+</sup> and B220<sup>+</sup> cells were readily capable of being mGFP<sup>+</sup> whereas in the cLP, this shifted to also include natural killer (NK) cells (Figure 5, G and H). Together, these results indicate that CD11c<sup>+</sup> DCs and macrophages in the gut are able to transfer GFP-labeled lipids to a variety of immune cells in the GI tract.

**DC-derived exosomal miR-146a is delivered to gut macrophages and alters their skewing in vivo.** RAB27A has been implicated in other secretory functions besides exosome secretion; therefore, we tested whether RAB27A-dependent myeloid cell–derived exosomes were involved in the worsened colitis phenotype. Additionally, the therapeutic potential of exosomal miRNAs holds great promise, as they would be based on a natural delivery system that has been optimized by evolution. To examine the functional impact of exosomal miR-146a and determine its efficacy as a potential IBD therapy, we administered vehicle (PBS) or approximately 10<sup>9</sup> WT or miR-146a<sup>−/−</sup> BMDC exosomes i.p. on days 2, 4, and 6 to mice challenged with DSS colitis over 8 days (Figure 6A). We observed shorter colons in Vav-Rab27a cKO animals that received miR-146a<sup>−/−</sup> exosomes than in those that received WT, miR-146a–sufficient exosomes (Figure 6B). These shorter colons were akin to KO mice given vehicle, whereas the WT exosomes restored KO colon length to near WT length. At the cellular level, CD38<sup>+</sup> M1-like proinflammatory macrophages were at higher levels (Figure 6C), and EGR2<sup>+</sup> M2-like antiinflammatory macrophages were at lower levels in mice that received miR-146a<sup>−/−</sup> versus WT exosomes (Figure 6C). These results phenocopy the macrophage profile observed in Rab27a cKO mice and show that the administration of WT exosomes to Rab27a cKO mice skews these macrophages back to WT proportions of M1- and M2-like populations.

We next sought to identify the coding mRNA direct targets that were repressed by miR-146a in this setting and determine if this macrophage skewing could be replicated in vitro. We generated WT BM-derived macrophages (BMDMs) and BMDCs from WT and miR-146a<sup>−/−</sup> mice over the course of 7 days. After this differentiation period, we isolated exosomes from the DCs (either WT or miR-146a<sup>−/−</sup>) and administered them to WT macrophages without any other stimulus to determine if miR-146a was sufficient to skew the BMDMs as we had seen in vivo (Figure 6D). Results indicated that these BMDMs were skewed by the presence or lack of miR-146a in the exosomes. When miR-146a was lacking from the exosomes, BMDMs were more M1-like than when the miRNA was present (Figure 6, E and F). Interestingly, we were also able to see that without miR-146a present in exosomes, WT BMDMs had increased levels of Traf6, Irak-1, and Nlrp3 transcripts (Figure 6G). These proinflammatory mediators are known targets of miR-146a and illustrate the functional capacity of the miRs loaded into these exosomes. Collectively, these data provide evidence that miR-146a can be transferred in an RAB27-dependent manner from CD11c<sup>+</sup> myeloid cells to gut immune cells to regulate macrophage populations known to drive inflammation during DSS colitis.

**Dysregulation of genes critical to exosome release, loading, and increased miRNA expression in patients with IBD.** We next explored whether these findings were applicable to human patients with IBD. The Gut Cell Atlas scRNA-Seq data set was mined to determine RAB27A and RAB27B expression from immune cells isolated from non-diseased human colons and mLNs. Similar to mice, expression profiles of RAB27A and RAB27B were distinct. Within the colon, RAB27A was largely detected in IgA<sup>+</sup> plasma cells, Th1 and Th17 cells, γδ<sup>+</sup> T cells, myeloid cells, and CD8<sup>+</sup> T cells (Figure 7A). Within the mLNs, we observed the highest RAB27A expression in follicular and memory B cells, NK cells, T follicular helper (Thf) cells, central memory T cells, CD8<sup>+</sup> T cells, and Tregs (Figure 7B). This dichotomous expression highlights the diverse roles of this GTPase and the importance of its function within the intestinal compartment. RAB27B also displayed a distinct expression pattern, with the highest expression in the mast cell cluster and dispersed expression in colonic T cell clusters (Figure 7A). Within the mLNs, RAB27B expression increased in NK cells and shifted to other T cell clusters such as Thf cells (Figure 7B). Importantly, the cell clusters RAB27A and RAB27B are detected within are dysregulated in patients with IBD according to scRNA-Seq, suggesting disease relevance of these 2 small GTPases (44).
Figure 4. Profiling of miRNAs within colon and BMDC-derived exosomes. (A) Density measurements of iodixanol gradient overlaid on top of NTA of each fraction of colon iodixanol gradient. (B) Venn diagram of differentially enriched miRNAs between colon EVs and BMDC EVs (n = 3). (C) Heatmap of the 3 groups within B. (D) miRNA qPCR confirmation of miR-146a, miR-155, and let-7d-7 from SI or colon EV preps (n = 3). (E) Percentage of mGFP+ vesicles of fluorescent vesicles from mTmG, Villin-Cre mTmG, Vav-iCre mTmG, and CD11c-Cre mTmG mice as measured by Aria II (n = 6–10). (G) Schematic of flow-sorting vesicles from colon explants of H and I. (H) Volcano plot of differentially expressed miRNAs highlighting miRNA enrichment in BMDC EVs. Dashed line, fold change of −2/2. (I) Representative flow plot of sorted mTmG vesicles with overlay of gated vesicles to be sorted from both a WT mouse and Vav-Cre mTmG mouse. (J) miR-146a, miR-342-3p, miR-141, and miR-223 expression in GFP+ sorted vesicles from Villin-Cre mTmG and Vav-iCre mTmG colon explants (n = 7). Data representative of 2 independent experiments. Unpaired 2-tailed t test for bar graphs. *P < 0.05. n.d., not detected.
Next, we assessed a cohort of 17 UC, 10 CD, and 27 noninflamed nondiseased patient samples to determine potential changes in RAB27A and RAB27B expression during disease (Table 1). Significantly decreased RAB27A expression was observed within patients with UC compared with nondiseased patient tissue, while no difference in RAB27B expression was found, consistent with results from our mouse model that RAB27A is a critical regulator of gut inflammation (Figure 7C). We assessed if this was specific to UC and found that RAB27A expression was not altered in patients with CD compared to noninflamed, nondiseased controls. However, RAB27B was increased, suggesting context-dependent effects on their expression (Supplemental Figure 5A). We speculate that this reduction in RAB27A expression affects exosome-mediated modulation of the immune response to UC. Consistent with this, increased IL-17A and NOS2 expression was observed in patients with UC and CD, suggesting an increase in Th17 cells and “M1-like” macrophages, similar to our Vav-Rab27A cKO mice (Figure 7C and Supplemental Figure 5A).

Next, expression of several miRNAs in the different patient samples was assayed. Increased expression of MIR-146A and MIR223 was observed, 2 miRNAs previously shown to be dysregulated in patients with UC (41, 45) (Figure 7D). Further, increased MIR342, MIR222, and MIR155 expression was also observed in patients with UC compared with nondiseased patients, similar to the observed increases in these miRNAs in BMDC-derived exosomes (Figure 4J and Figure 7D). Finally, miR-9 was unchanged between groups, highlighting that only a subset of miRNAs found in exosomes are dysregulated in patients with UC. Interestingly, although there was a distinct increase of these miRNAs in patients with UC, with the exception of MIR223, no difference was found in patients with CD, suggesting that there could be a distinct mechanism of action for exosomes within this disease that remains to be elucidated (Supplemental Figure 5). Further, one could interpret this increase in miRNA levels to indicate buildup of these miRNAs within cells with reduced Rab27A expression and thus impaired exosome release.

In recent years, it has been appreciated that the sorting of miRNAs into exosomes can be regulated by RNA-binding proteins (RBPs). Due to our observed preferential sorting of miR-223 into mouse DC-derived exosomes and the alterations to RAB27A and miRNA levels, we also determined if the known miR-223 exosome sorting protein, Y-box binding protein 1 (YBX1), as well as other known RBPs, were altered in patients with IBD (46, 47). Interestingly, YBX1 expression was significantly decreased in both diseased states, suggesting that decreased loading of miR-223 and possibly other miRNAs by YBX1 may be occurring (Figure 7E). Additionally, we saw specific decreases in expression of the RBPs, FUS and HNRNPA2B1, but no changes to ALYREF or SYNCRIP, despite all of these proteins having reported roles in miRNA sorting into exosomes (Figure 7E and Supplemental Figure 5) (48, 49). This observation leads us to hypothesize that there may be defects in both exosome secretion and miRNA loading in patients with IBD, potentially a unique mechanism behind the progression of these heterogenous diseases.

Discussion

Utilizing exosomes in a therapeutic manner represents an attractive autologous approach moving forward. Exosomes can be derived from patients’ blood cells, including DCs that can first be expanded and differentiated ex vivo and subsequently administered autologously to deliver molecular cargo with therapeutic benefits (50, 51). However, identifying and characterizing endogenous roles for exosomes and their cargo, such as miRNAs, remains a key step toward acquiring the foundational knowledge required for careful design of effective technologies. Here, we identified a potentially novel mechanism whereby CD11c+ myeloid cell–derived, Rab27a-dependent exosomes regulate intestinal inflammation, and this occurs in part through miR-146a–mediated impacts on inflammatory macrophage cellular identity and function in the gut. Of clinical relevance, administration of DC-derived miRNA-containing exosomes was able to rescue Rab27a-dependent colitis phenotypes in mice, and dysregulated RAB27A and miRNA expression was observed in a cohort of patients with IBD. To our knowledge, this is also the first study demonstrating
A

Donors:
PBS
Rab27A fl/fl
Vav-Cre Rab27A fl/fl

Recipients:
PBS
Rab27A fl/fl EVs
miR146a-/- EVs

2.5% w/v DSS
Harvest

B

NS
NS
NS

Colony Length (cm)

% CD38+ (M1 Macrophages)

% Egr2+ (M2 Macrophages)

Rab27A fl/fl + PBS
Vav-Cre Rab27A fl/fl + PBS
Vav-Cre Rab27A fl/fl + fl/fl EVs
Vav-Cre Rab27A fl/fl + miR146a-/- EVs

C

"M1" Macrophages

"M2" Macrophages

D

BMDCs

BMDCs

WT

WT

WT

miR-146a-/-

E

WT + WT EVs

WT + miR146a-/- EVs

Egr2+

CD38+

F

% M1 Macrophages

% M2 Macrophages

G

Traf6

Irak-1

Nlrp3

Expression

Expression

Expression

BMDMs

BMDCs

WT

WT

WT

miR146a-/-

WT

WT

WT

miR146a-/-

WT

WT

WT

miR146a-/-

https://doi.org/10.1172/jci.insight.159469
that DC-derived exosomes functionally influence macrophage skewing in the GI tract, an important innate immune subset thought to drive colitis disease (44).

We clearly observed defective exosome release from DCs lacking Rab27A, and this was accompanied by increased DSS colitis disease severity. Additionally, we saw that in a different model of IBD based on blocking IL-10R, we observed an exacerbated colitis disease phenotype when Rab27a was deleted from CD11c+ DCs and macrophages. This demonstrates that this mechanism is broadly applicable and not specific to one preclinical model. To our surprise, yet demonstrating specificity, we also found that Rab27a and Rab27b were dispensable within the IEC compartment during DSS-induced colitis despite high expression in IECs. We acknowledge that these GTPases may play pivotal roles in other homeostatic or disease contexts in the gut not explored here. Further, we have also ruled out a contribution by Rab27a-dependent, T cell-derived exosomes and Rab27b-dependent, hematopoietic derived exosomes in regulating gut inflammatory responses during DSS colitis. In addition to identifying cell-specific functions for Rab27 proteins, future work using our Rab27-floxed mice will enable us and others to further determine and define Rab27-dependent and Rab27-independent EV populations in vivo.

In addition to selectively blunting EV release using Rab27 cKO mice, it is critical to identify and visualize released exosomes in order to further understand their biology. Exosome researchers have studied the biodistribution of EVs following injection in vivo, but few tools exist to track EVs after their release from the cells of origin in vivo (52). The use of FACS-based methods to detect and purify exosome membrane fluorescence triggered by Cre-mediated labeling using mTmG mice is an emerging strategy (53) and builds on previous methods that used lipid-labeling dyes like PKH67 to sort vesicles (54). This innovative sorting method allowed us to separate IEC-derived exosomes from hematopoietic cell-derived exosomes to determine the source of specific exosome cargo, including miRNA species. We were also able to pair this with ImageStream technology to visualize fluorescently labeled lipids associating with specific cell types in vivo, highlighting the importance of this and other emerging technologies in the EV field (55). In the future, we will combine this reporter system with our Rab27 cKO mouse lines to tease apart the roles of Rab27a and Rab27b in distinct vesicle population release in vivo, which can be tracked as vesicles migrate to target cells. This approach can also be applied to other related conditions, such as colon cancer, where the roles of exosomes from tumors and/or hemopoietic cells in modulating immune responses still confound our understanding of such pathologies despite exciting initial reports (56–58). Additionally, future work on distinct miRNA profiling signatures of purified exosomes, such as we have done here, can be integrated with established miRNA target databases, such as HITS-CLIP (59). These types of analyses will provide additional insight into the functional effects of exosomal miRNAs on target cells. Further, several RBPs, including YBX1 (46, 60), showed reduced expression in IBD patient samples. This finding opens the door to interrogate the relevance of these proteins in intestinal disease. Future work will be needed to unravel the roles these proteins play in loading specific miRNA contents into EVs prior to their release in the gut.

Treating inflammatory disorders through immune regulation in the gut remains a challenging clinical endeavor. For instance, not all patients respond to anti-TNF treatments, and there are potent off-target effects of current cytokine-based immunotherapies (61). The biological efficacy of our exosome delivery experiments in mice undergoing experimental colitis provides the groundwork for future DC-based EV miRNA mimic therapies (62). This could be used to alleviate IBD symptoms caused by aberrant macrophage activation and M1 skewing or inflammatory T cell responses, 2 critical immune populations responsible for IBD pathology (63), and will be improved through targeted loading of specific miRNAs to levels with optimal therapeutic impact. Although we identified exosomal miR-146a as a critical regulator of GI macrophage skewing, additional exosomal miRNAs beyond miR-146a that are involved in Th17 inhibition in BMDC exosomes remains unclear, along with the functional relevance of additional exosome cargo. We did identify miR-222 as a DC exosome-enriched miRNA, and it has been reported that this miRNA along with miR-221 cell-intrinsically regulates Th17 cells within the gut (64). Future research will allow us to discern if this is an exosome-mediated...
mechanism of immune regulation as well. Also, of note, RAB27A, YBX1, and the exosomal miRNAs identified in our mouse studies were also dysregulated in a cohort of patients with UC, further supporting the translational potential of our work by suggesting that exosome replacement therapy may replenish antiinflammatory EV levels during disease. Taken together, our study points to exosomes and their cargo as promising targets of next-generation therapeutic strategies to treat inflammatory diseases in the GI tract.

Figure 7. Dysregulation of RAB27A, inflammatory genes, and miRNA signatures in patients with UC. (A) Analysis of RAB27A and RAB27B expression in human baseline colon samples from the Gut Cell Atlas wherein a dot represents detection of transcript (7). Clusters as previously annotated. (B) Analysis of RAB27A and RAB27B expression in human baseline mLN samples from the Gut Cell Atlas (7). (C) qPCR analysis of RAB27A, RAB27B, IL-17A, and nitric oxide synthase 2 (NOS2) in non-IBD (n = 27) and UC patient (n = 17) colonic samples. (D) miRNA qPCR analysis of miR-146a, miR-223, miR-342, miR-222, miR-155, and miR-9 in C. (E) qPCR analysis of YBX1, HNRNPA2B1, FUS, ALYREF, and SYNCRIp in C. Quartiles marked with dashed lines. Unpaired 2-tailed t-test for all violin plots. *P < 0.05, **P < 0.005, ***P < 0.0005. See also Supplemental Figure 5.
Methods

Mice. All mice are on the C57BL/6 background. Rab27DKO (Rab27a<sup>ash/ash</sup>, Rab27b<sup>−/−</sup>) mice were provided by T. Tolmachova and M.C. Seabra (CEDOC, NOVA Medical School, NMS, Universidade NOVA de Lisboa, Lisbon, Portugal) as previously reported (27). Floxed Rab27a (Rab27a<sup>fl/fl</sup>) and Rab27b (Rab27b<sup>fl/fl</sup>) mice were custom generated with the aid of Biocytogen and CRISPR/Cas9-based technology. For Rab27a, Cas9 cut sites were made flanking exon 4. The upstream guide RNA (gRNA) was GGACCCCCTGTACGTTAAAAGC and the downstream gRNA was GGTCCCGACCAGATGTTCCACC. For Rab27b, Cas9 cut sites were made flanking exons 3 to 4. The upstream gRNA was GGTCTTAAGAATTTATCAACTGG and the downstream gRNA was GGCACTCCTACATCCAAGGC. Following the genomic cuts, approximately 1.5 kb homologous regions containing loxP sites were injected into zygotes to create founder mice. Southern blots were used to confirm positivity for the 5′ loxP site and no random insertion using an internal probe. Mice were verified by junction PCR, using 5′ forward and 3′ reverse for each gene set, and confirmed loxP insertion and correct excision by PCR. We bred these to Cre driver strains, with the female always being hemizygous for Cre<sup>+</sup> and the male homozygous for Cre<sup>−</sup>. All Cre driver strains were ordered from The Jackson Laboratory (JAX): Villin1-Cre (JAX 004586), CD4-Cre (JAX 022071), CD11c-Cre (JAX 008068), and Vav-iCre (JAX 008610). mTmG mice (JAX 007676) were bred with multiple Cre lines (40, 53). Floxed site primers were used to genotype as described below. Littermates and both sexes were used for all experiments, and mice were 8–12 weeks old at time of experiments. The use of littermate controls allowed for proper control of the microbiota as is standard in the field.

scRNA-Seq analysis. ScRNA-Seq mining was done using the Broad Institute’s Single Cell Portal database. All clusters remained the same as the original manuscript’s analysis (31). Human data were mined from the Gut Cell Atlas (https://www.gutcellatlas.helmsleytrust.org) (7).

Colonic explants. Explants were generated by removing the entire colon or the distal 15 cm of the SI. Any remaining connective tissue was removed from the outside of the tissue and then tissue was gently

---

**Table 1. Characteristics of Cleveland Clinic patients with IBD**

| Characteristics               | Non-IBD controls (<i>n</i> = 27) | UC (<i>n</i> = 17) | CD (<i>n</i> = 10) |
|------------------------------|----------------------------------|-------------------|-------------------|
|                              | percent or mean (SD)             | percent or mean (SD) | percent or median (SD) |
| **Demographics**             |                                  |                   |                   |
| % Male                       | 48%                              | 53%               | 60%               |
| % Female                     | 52%                              | 47%               | 50%               |
| Age 18–40 (y)                | 52%                              | 53%               | 50%               |
| Age 40+ (y)                  | 48%                              | 47%               | 50%               |
| Hispanic, African American,  | 11%                              | 12%               | 10%               |
| Native American, Asian,      |                                  |                   |                   |
| Pacific Islander             |                                  |                   |                   |
| Not Hispanic, African        | 89%                              | 88%               | 90%               |
| American, Native American,   |                                  |                   |                   |
| Asian, Pacific Islander      |                                  |                   |                   |
| **Disease characteristics**  |                                  |                   |                   |
| Years from IBD diagnosis     | -                                | 6.7 (8.2)         | 6.6 (9.3)         |
| Active disease               | -                                | 65%               | 60%               |
| Disease location (colon)     |                                  |                   |                   |
| Ascending/Transverse         | -                                | 47%               | 50%               |
| Descending/Sigmoid           | -                                | 11%               | 10%               |
| Rectum                       | -                                | 11%               | 10%               |
| Multiple regions             | -                                | 30%               | 30%               |
| **Medication use**           |                                  |                   |                   |
| Aminosalicylates             | -                                | 24%               | 40%               |
| Steroids                     | -                                | 37%               | 23%               |
| Immunomodulators (6-mercaptopurine, azathioprine, or methotrexate) | - | 31%   | 55%               |
| Biologic therapy (infliximab, adalimumab, certolizumab pegol, and natalizumab) | - | 27% | 57%               |
flayed open. Fecal and mucus contents were gently removed with forceps and placed in a 6-well plate with 1× PBS. After a brief wash with 1× PBS, tissues were placed in 15 mL Falcon tubes (VWR) in a tissue culture hood with 5 mL of complete RPMI 1640 medium (10% FBS, HEPES, sodium pyruvate, nonessential amino acids, 100 U/mL penicillin/streptomycin, and l-glutamate). Tubes were placed horizontally in a container and shaken for 25 minutes at room temperature (RT), at a speed sufficient to maintain gentle movement of the tissue. After this incubation, tissues were plated in 10 cm dishes with 20 mL of complete exosome-depleted RPMI (the same media as complete RPMI above but supplemented with 10% exosome-depleted FBS, Systems Biosciences) and then placed in a 37°C 5% CO₂ incubator for 16 hours. The supernatant of these plates was used to isolate vesicles, as described below.

**NTA.** Size and concentration of isolated particles were determined using the Nanosight NS300 (Malvern Technologies). For each sample, three 60-second videos were taken at 25 frames per second. The detection threshold was maintained for each sample to ensure consistent measurement of particles.

**Vesicle isolation.** Vesicles were isolated as described (26). Briefly, supernatants were centrifuged for 10 minutes at 1,000g, then 10 minutes at 2,000g, both at 4°C (Eppendorf 5810 R centrifuge with A-4-81 rotor). Supernatants were transferred to Oak Ridge tubes (Thermo Fisher Scientific) and spun for 30 minutes at 10,000g and 70 minutes at 100,000g, both at 4°C, in a Thermo Fisher Scientific Sorvall Lynx 6000 with a T26-8 × 50 rotor. Pellets were washed with 25 mL of 1× PBS and spun at 100,000g for 70 minutes at 4°C. After removing PBS, pellets were resuspended in 0.02 μM filtered 1× PBS. To purify colonic EVs for miRNA sequencing, we resuspended the final pellet in 30% iodixanol gradient instead of PBS (65). A base solution of 60% iodixanol (in water, 0.5 M sucrose, 20 mM Tris pH 7.4, and 2 mM EDTA) was made followed by working solutions (WSs) of 40%, 30%, and 20%. The 30% solution was the basis of the gradient (2.5 mL), followed carefully by 1.05 mL of 20% (from 40% WS), and then finally 0.95 mL of 10% (from 20% WS). We spun this at 350,000g for 1 hour at 4°C with no brakes in a swinging bucket SW55Ti rotor (Beckman Optima L-90k Ultracentrifuge). We analyzed 500 μL fractions by NTA, and fraction 2 showed enrichment for vesicle-sized particles and was the expected density. This was then spun down at 100,000g for 30 minutes at 4°C with no brake, then resuspended in a small volume, and 700 μL QIAzol (QIAGEN) was added for further RNA analysis.

**mLN tissue prep.** MLNs were harvested and placed on a 40 μM filter (Thermo Fisher Scientific) in a 6-well plate with 5 mL complete RPMI. After being dissociated through the filter with the back end of a sterile 1 mL syringe, cells were spun down in 15 mL Falcon tubes at 400g for 5 minutes and then resuspended in 1 mL complete RPMI 1640 before cell counting with trypan blue solution (VWR). Similar cell numbers were plated for flow analysis.

**Colonic lamina preparation.** Immune cells were harvested as described (41, 66, 67). Briefly, murine colons with attached ceca were harvested and placed in 1× PBS in 6-well plates on ice. Remaining fat, connective tissue, and the cecum were removed. Colons were splayed and mucus and feces were removed from the colon before returning to the plate. Once all colons were cleaned, each colon was diced on a Petri dish lid using a razor blade and placed in a separate 50 mL tube. A total of 10 mL of prewarmed dissociation solution (1× HBSS without Ca²⁺ and Mg²⁺, 1.5 mM DTT, 10 mM HEPES, and 30 mM EDTA) was added and the tubes vortexed. Colons were incubated for approximately 25 minutes at 37°C with shaking at 150 rpm until solutions were cloudy from IECs' separation. Samples were vigorously shaken 3 times, vortexed for 15 seconds, then poured over a 100 μM filter on a 50 mL conical tube to remove nonimmune cells such as IECs, and the filters were rinsed briefly with 2 mL of ice-cold 1× PBS. The remaining tissue was collected on the filter with forceps and moved to a new 50 mL conical tube. A total of 15 mL of prewarmed digestion solution (1× HBSS with Ca²⁺ and Mg²⁺, 5% FBS, DNase, collagenase D, and dispase) was added. Samples were vortexed and incubated for 45 minutes at 37°C with shaking at 150 rpm until solution became cloudy. Samples were shaken 3 times and vortexed for 15 seconds. To collect the remaining immune cLP cells, the digested tissue was then poured over a 40 μM filter on a 50 mL conical tube containing 10 mL 1× PBS. Samples were next rinsed with 2 mL of ice-cold 1× PBS and spun at 800g for 10 minutes at 4°C. Next, supernatant was removed and discarded with vacuum. Cells were then resuspended in 500 μL of complete RPMI 1640 and counted following trypan blue exclusion staining.

**qPCR.** RNA was isolated following manufacturer protocols using the QIAGEN miRNeasy Mini or Micro Kit. Vesicle samples were prepped with Micro kits due to low RNA concentration. Mouse tissue and cell isolates were prepped with Mini kits due to a higher abundance of RNA. cDNA was generated according to manufacturer’s protocols with qScript cDNA SuperMix (QuantaBio) for mRNA
(using 400 ng RNA input) and miRNA LNA RT kit (QIAGEN) for miRNA reactions (100 ng RNA input). All miR primers were predesigned and ordered from QIAGEN. qPCR reactions used PowerUp SYBR Green Master Mix (Applied Biosciences) according to manufacturer’s protocol and 500 nM primer reaction mixes generated from primer stocks synthesized at the University of Utah DNA/Pep tide Facility (Table 2). All reactions were run on an Applied Biosciences Q56 Thermocycler.

**DSS colitis.** Animals were given 2.5% w/v DSS (MP Biomedicals MW 36,000–50,000) in their drinking water, replaced every other day. Mouse weight was measured daily and if animals reached 80% of their starting weight, they were culled. Colon length was measured from rectum to below the cecum.

**aIL-10R colitis.** Mice received i.p. injection of 1 mg mAb/100 μL/20 g mouse weight (Bio X Cell; catalog BE0050) (34). Mice were monitored for weight loss and rectal prolapse over 5 weeks, biweekly. Mice were culled if body weight was 20% less than starting weight.

**BM chimera.** Mice were lethally irradiated as described previously (27). After irradiation, mice were retro-orbitally injected with 10 million RBC-depleted BM cells isolated as below. Mice reconstituted their hematopoietic systems for 12 weeks before isolating CD11b+ and CD3+ cells by FACS from the cLP and mLNs.

**Serum isolation.** Serum was isolated from mouse heart blood kept on ice until centrifugation. Spins at 500g were done twice for 10 minutes each and supernatants saved at each time. Serum was stored at −80°C until used for ELISAs.

**Colon histology and scoring.** Colonos were fixed in 10% buffered formalin phosphate solution after removal of fecal contents and then transferred to 70% ethanol at 4°C until staining. Sectioning and H&E staining were done at the Huntsman Cancer Institute (HCI) Biorepository and Molecular Pathology Shared Resource in the ARUP operated Research Histology division. DSS colon scoring was done in a blinded manner with the following rubric scales: percentage of colon crypt loss (0.5 [5%] to 7 [>75%]), crypt loss severity (1 [partial loss] to 5 [full loss]), and inflammatory aggregates (1 [1 to 3] to 3 [>7]). For aIL-10R colon scoring, colon sections were prepared in the same manner as DSS colitis. Additionally, colon sections were stained for Alcian blue to assess goblet cell loss (34, 36). Scoring was done in a blinded fashion with the following scale: epithelial hyperplasia — 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe); goblet cell loss — 0 (none), 1 (slight depletion), 2 (mild), 3 (moderate), 4 (few mucin-containing cells remaining); inflammatory aggregates — 0 (none), 1 (1–2 in LP), 2 (several mononuclear cell infiltrates in LP), 3 (involves submucosa, rarely transmural), 4 (transmural); and crypt abscesses — 0 (none), 1 (small epithelial cell erosions), 2 (ulcers observed), 3 (crypt abscesses and ulcers present). QuPath software was utilized to measure epithelial cell crypt depth with measurements taken along the entire colon length; additionally, inflammatory aggregates were quantified.

**Flow cytometry.** Samples were blocked with CD16/32 Abs (BioLegend catalog 101302) for 20 minutes at 4°C. After pelleting at 400g for 5 minutes at room temperature, cells were stained for 30 minutes at the dark at 4°C. Dilutions of BioLegend antibodies (unless otherwise noted) are as follows: splenocyte FACS (Figure 1): CD3-PacBlue (100334; 1:250), B220-FITC (103206, 1:500), CD11b-PerCP/Cy5.5 (101228, 1:1,000), CD4-PE (100408, 1:2,000), and CD8-APC (100712, 1:2,000). Macrophage panel (Figures 2, 3, and 6): CD45-FITC (103108), CD64-BV711 (139311), CD11c-PerCP/Cy5.5 (117328), CD11b-BV605 (101237), MHCIIP-PacBlue (107620), CD38-PE/Cy7 (102717) (all 1:250), and Egr2-APC (eBioscience 17-6691-82, 1:50). Th17 panel (Figures 2, 3, and 5): CD45-FITC, CD3-APC/Cy7 (100222), CD4-PacBlue, IL-17-APC (eBioscience 17-7177-81), and RORγT-PE 610 (eBioscience 61-6981-82) (all intracellular stains 1:50, all surface stains 1:250). ImageStream (Figure 5): CD45-PE/Cy7 (103114), CD3-APC/Cy7, CD4-Pac Blue, CD11b-BV605, and Ghost Dye – BV510 (Tonbo Biosciences 13-0870-T100). After staining, cells were washed twice for 5 minutes each with column buffer (1× HBSS without Ca and Mg, HEPES, EDTA, and FBS). Surface stain–only cells were fixed overnight with 1% paraformaldehyde and washed in column buffer twice before analysis. If intracellular staining was necessary, the FoxP3/Transcription Factor Staining Buffer Kit (Tonbo Biosciences) and protocol was followed. All samples were then resuspended in 300 μL of column buffer and run on a BD LSR Fortessa after compensating with UltraComp eBeads (Thermo Fisher Scientific) and using single-stain controls.

**ELISA.** Lipocalin-2 ELISAs were performed according to manufacturer’s protocol (Thermo Fisher Scientific DY 1857-05). Dilutions of serum were made according to sickness of animals but ranged from 1:500 to 1:1,000.

**miRNA-sequencing/bioinformatic analysis.** miRNA-sequencing and bioinformatic analyses were done as described previously using the University of Utah Bioinformatic Analysis core services (68). The cutoffs
for miRNAs used for comparison between colon and DCs were P adj. < 0.05 and base level detection of at least 100.

**ImageStream analysis.** mLN samples were run on the Amnis ImageStream MKII Imaging Flow Cytometer using 405, 488, 561, 642, and 785 nm excitation lasers and 60× original magnification. Analysis was done with IDEAS software, and cells were gated based on their bright-field gradient RMS (average slope spanning 3 pixels in an image) as a measure of focus, followed by their area and aspect ratio to exclude debris and aggregates. CD45⁺CD3⁺CD4⁺ or CD45⁺CD3⁻CD11b⁺ cells were analyzed for tdTomato surface staining and GFP⁺ puncta.

**FACS.** Isolated vesicles from ultracentrifugation were diluted in 1 mL of 0.02 M filtered 1× PBS and sorted on a BD FACSAria cell sorter using the violet laser as the side scatter (SSC) and setting the forward scatter and SSC on a logarithmic scale. Fluorescent beads of known sizes (110 nm and 500 nm, SBI EXOF300A-1) were used to ensure properly sized vesicles were isolated. After sorting based on membrane fluorescence, vesicles were spun down at 100,000 g in 5 mL of 1× PBS (0.02 M filtered) for 30 minutes, and the pellet was resuspended in QIAzol for RNA isolation and miRNA qPCR.

**BMDCs/BMDMs and exosome administration to mice.** BMDCs and BMDMs were generated as previously described (27, 69). Briefly, 10 million BM cells were plated in 15 cm dishes with 20 mL of complete RPMI supplemented with GM-CSF at 20 ng/mL. After 4 days, new GM-CSF was added in 10 mL of complete RPMI. After 7 days, vesicles were isolated with ultracentrifugation. For injection experiments, 10⁹ vesicles were injected i.p. after size and concentration confirmation by NTA on days 2, 4, and after start of DSS treatment. Vesicles were sex-matched, when possible; otherwise only female BMDC-derived vesicles were used to prevent potential immune stimulation by Y antigen. For BMDMs, a total of 6 million BM cells were plated in 10 cm dishes with 10 mL of complete DMEM (penicillin/streptomycin, l-glutamine, FBS) supplemented with M-CSF at 20 ng/mL. After 4 days, new M-CSF was added in an additional 5 mL of complete DMEM. All cells were generated from mouse lines described in this study.

---

**Table 2. Primers**

| Gene               | Forward (5’→3’)                                         | Reverse (5’→3’)                          |
|--------------------|--------------------------------------------------------|------------------------------------------|
| Mm Rab27A         | TTCAGGGAAAAGAGAGTGTTGACAG                               | CTTGTCTTATTTCGTACAGGACACAG               |
| Mm Rab27B         | GAAGGCTGCTGAGGTGGACAGCC                                | TTTAAAGCTTCTCCTGAGCTCCATT                |
| Mm Traf6          | TACTCATGCTAGGATTCAGCACA                                 | CACCTGTTCCGTAAAAGGACACC                  |
| Mm Irak-1         | TGTGCCGGTCTTCAAAAGT                                    | TGTAAGAAGCATGCAGCTTAG                   |
| Mm Nlrp3          | ATCAACAGGACAGCAGCAGCC                                  | GCTCTCTGGAATACCAAA                      |
| Rab27A 5’ fl      | ATGGTTGCTTTTAAAGAGACAGGACT                             | AGCCAGGTTTTACCTGTTGGCCATA               |
| Rab27A 3’ fl      | CAGCTCTGAGAGTGATTCAGCAA                                 | CAGCTCTGAAAGCAGCTTAG                   |
| Rab27B 5’ fl      | GGAGAGGAGGAGAGCAGACG                                   | TGCAGAATACCAAGACCC                      |
| Rab27B 3’ fl      | ATCTTGCTCAACATATGCCA                                   | AGCCAGGACACAGGT                         |
| Vav-iCre          | GTTGTGTTGATTGTCAGCACA                                    | CAGCAGTGGTGCCAAGAGT                    |
| Villin1-Cre       | ACCCCCATAGGAAAGACGAGG                                | GCTTTTACTGCAGCAGACGCC                   |
| CD4-Cre WT R and common F | GTTCTTTGATATATATGGAATGTCAGGCC                        | TATGCTCTAAAGACAAAGAATTTGACA             |
| CD4-Cre Mut R     | -                                                      | CTGCAAGGGTGAACACAC                      |
| CD11c-Cre control | CAAATGTTGCTTCTGCTGTG                                    | GTCACTGAGAGGACAGT                       |
| CD11c-Cre transgene | ATCTGAGGAGAGGAGTGGCACA                                 | GGCAACATCAGGATACCC                      |
| mTmG WT F and common R | AGGAGCTGCTGAGTCAGGAGT                                  | TTTCAGCCTGACGCCCCACA                    |
| mTmG Mut F        | TAGAGAAGCCGGGAAACCTT                                   | -                                       |
| HS Rab27A         | GAAGGCTGCTGAGGTGGACAGCC                               | CACAGCTTCTGCTTAGCC                      |
| HS Rab27B         | ATCTTGCTCAACATATGCCA                                   | TGCAGTGGGTTTCCTCCG                      |
| HS IL-17A         | CTGCTGGCTGCTGAGGAGCAGC                                 | AGGAGCAGTGGTGCCAAGGT                    |
| HS Nos2           | TACCAGCTCAACATATGCCA                                   | TGCAGTGGTGCCAAGGT                      |
| HS YXBI           | GACAGAGAAGCCCCGAGACTCAG                                  | CAGCTGCTGAGTACCC                      |
| HS HNRNP2AB1      | ATTGATGGAGAGGATGTTACCCCC                                     | AATTCCGAAACCAAGCAGGT                   |
| HS FUS            | ATGCGGCTCAGAGGTTATACCA                                 | GTAACCTGCTGAGTCTGACCC                   |
| HS AYREF          | ACAGGCAGACAGGCTGCTGAC                                    | TCTAGCTATGCAAGACCT                     |
| HS SYNCRIP        | CTGTTCTCAATAAGAGGTTACCC                                  | TCCGGTTGGTGTTATATATATGTG               |

---

**JCI Insight 2022;7(19):e159469  https://doi.org/10.1172/jci.insight.159469**
**Human samples.** All specimens were of colonic origin and diagnoses were confirmed by clinical criteria. Non-IBD (control) tissues were obtained from histologically normal, noninflamed large bowel specimens from patients admitted for bowel resection because of conditions including colon cancer, benign polyps, diverticulitis, and colonic inertia. The mucosal layer of each colon was dissected and washed, and surface debris was removed by blotting the tissue with paper towels multiple times. The mucosal layer was then removed and cut into small strips (~0.5 cm) and snap-frozen in liquid nitrogen. All specimens were age and sex matched.

**Schematics.** All schematics and graphical abstract were created with BioRender.com.

**Statistics.** All statistical analysis and graphing were done in GraphPad Prism 9.0 software. Data represent mean ± SEM. *P* > 0.05 was nonsignificant, *P* < 0.05, **P** < 0.005, ***P** < 0.0005.

**Study approval.** Human intestinal tissue specimens were obtained within 2 hours after resection from patients undergoing surgery from the Department of Surgical Pathology at the Cleveland Clinic under an IRB-approved protocol. Mice were housed in a vivarium with a 12-hour light/12-hour dark cycle per day, temperatures of 22°C, and 20% relative humidity. Experimental mouse procedures and husbandry were performed with the approval of the IACUC of University of Utah.

**Additional methods details are in Supplemental Methods.**

**Author contributions**

Experiments were designed by KMB, DMW, ACP, WPV, WZS, JLR, and RMO and completed by KMB, MCN, WWT, TRC, DGB, AG, SHL, AMW, JEM, KAK, AGR, VBT, and JWT. Data analysis was done by KMB, MCN, WWT, TRC, DGB, and AG. Human samples were provided by ACP. Writing of the manuscript was done by KMB, JLR, and RMO and editing by KMB, MCN, DGB, DMW, WPV, WZS, MA, JLR, and RMO. This study was supervised by JLR and RMO.

**Acknowledgments**

The authors would like to thank members of the O’Connell and Round labs for critical reading and editing of this manuscript. We thank the DNA/Peptide Facility, part of the Health Sciences Center Cores at the University of Utah (U of U) for synthesizing all primers and the HCI High-Throughput Genomics Shared Resource for the library prep and miRNA sequencing. We thank the HCI Bioinformatic Analysis group and Flow Cytometry Shared Resource for analyzing miRNA-sequencing data and cell sorting, respectively. We thank the HCI Research Histology core for sectioning and H&E staining of mouse colons. We thank T Tolmachova and MC Seabra for providing Rab27DKO mice. KMB was funded by NIH grant T32 AI138945-1 and RMO by NIH grant AI123106-01A1.

Address correspondence to: 2000 Circle of Hope Dr. Rm 5210, Salt Lake City, Utah 84112, USA. Phone: 801.587.5684; Email: june.round@path.utah.edu (JLR); ryan.oconnell@path.utah.edu (RMO).

1. Brown EM, et al. The role of the immune system in governing host-microbe interactions in the intestine. *Nat Immunol*. 2013;14(7):660–667.
2. Faria AMC, et al. Tissue adaptation: implications for gut immunity and tolerance. *J Exp Med*. 2017;214(5):1211–1226.
3. van Niel G, et al. Intestinal epithelial cells secrete exosome-like vesicles. *Gastroenterology*. 2001;121(2):337–349.
4. van Niel G, et al. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol*. 2018;19(4):213–228.
5. Mitsuhashi S, et al. Luminal extracellular vesicles (EVs) in inflammatory bowel disease (IBD) exhibit proinflammatory effects on epithelial cells and macrophages. *Inflamm Bowel Dis*. 2016;22(7):1587–1595.
6. Zhang X, et al. Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. *Nat Commun*. 2018;9(1):2873.
7. James KR, et al. Distinct microbial and immune niches of the human colon. *Nat Immunol*. 2020;21(3):343–353.
8. Asyap KK, Moss AC. Exosomes in Intestinal Inflammation. *Front Pharmacol*. 2021;12:658505.
9. Karlsson M, et al. “Tolerosomes” are produced by intestinal epithelial cells. *Eur J Immunol*. 2001;31(10):2892–2900.
10. Van Niel G, et al. Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. *Gut*. 2003;52(12):1690–1697.
11. Mallegol J, et al. T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. *Gastroenterology*. 2007;132(5):1866–1876.
12. Valadi H, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9(6):654–659.
13. O’Connell RM, et al. Physiological and pathological roles for microRNAs in the immune system. *Nat Rev Immunol*. 2010;10(2):111–122.
RESEARCH ARTICLE

14. Treiber T, et al. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20(1):5–20.
15. Runtisch MC, et al. MicroRNAs and the regulation of intestinal homeostasis. Front Genet. 2014;5:347.
16. Park EJ, et al. MicroRNA-mediated dynamic control of mucosal immunity. Int Immunol. 2017;29(4):157–163.
17. Thomou T, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017;542(7642):450–455.
18. Mittelbrunn M, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282.
19. Nation GK, et al. Secret messengers: extracellular RNA communication in the immune system. Immunol Rev. 2021;304(1):62–76.
20. Barral DC, et al. Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J Clin Invest. 2002;110(2):247–257.
21. Ramalho JS, et al. Chromosomal mapping, gene structure and characterization of the human and murine RAB27B gene. BMC Genet. 2001;2:2.
22. Alexander M, et al. Rab27-dependent exosome production inhibits chronic inflammation and enables acute responses to inflammatory stimuli. J Immunol. 2017;199(10):3559–3570.
23. Ostrowski M, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19–30.
24. Mizuno K, et al. Rab27b regulates mast cell granule dynamics and secretion. Traffic. 2007;8(7):883–892.
25. Tolmachova T, et al. Rab27b regulates number and secretion of platelet dense granules. Proc Natl Acad Sci U S A. 2007;104(14):5872–5877.
26. Stinchcombe JC, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 2001;152(4):825–834.
27. Alexander M, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6:7321.
28. Okoye IS, et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity. 2014;41(3):503.
29. Menasche G, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173–176.
30. Xu AT, et al. Exosomes in intestinal mucosal immunity. J Gastroenterol Hepatol. 2016;31(10):1694–1699.
31. Biton M, et al. T helper cell cytokines modulate intestinal stem cell renewal and differentiation. Cell. 2018;175(5):1307–1320.
32. Haber AL, et al. A single-cell survey of the small intestinal epithelium. Nature. 2017;551(7680):333–339.
33. Menasche G, et al. Biochemical and functional characterization of Rab27a mutations occurring in Griscelli syndrome patients. Blood. 2003;101(7):2736–2742.
34. Saha P, et al. IL-10 receptor neutralization-induced colitis in mice: a comprehensive guide. Curr Protoc. 2021;1(8):e227.
35. Kuhn R, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263–274.
36. Garcia-Martin R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+)-TH1-like responses. J Clin Invest. 1996;98(4):1010–1020.
37. Erben U, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. In J Clin Exp Pathol. 2014;7(8):4557–4576.
38. Chiu NT, et al. Selective export into extracellular vesicles and function of tRNA fragments during T cell activation. Cell Rep. 2018;25(12):3358–3370.
39. Jeppesen DK, et al. Reassessment of exosome composition. Cell. 2019;177(2):428–445.
40. Muzumdar MD, et al. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45(9):593–605.
41. Runtisch MC, et al. MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget. 2015;6(30):28556–28572.
42. Garo LP, et al. MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat Commun. 2021;12(1):2419.
43. Li B, et al. miR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity. J Clin Invest. 2017;127(10):3702–3716.
44. Huang LJ, et al. Multitomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn's disease. Immunity. 2020;54(8):1728–1744.
45. Neudecker V, et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J Exp Med. 2017;214(6):1737–1752.
46. Shurtleff MJ, et al. Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. Elife. 2016;5:e19276.
47. Suresh PS, et al. YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling. Eur J Cell Biol. 2018;97(3):163–167.
48. Garcia-Martín R, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature. 2022;601(7893):446–451.
49. Villarroela-Beltri C, et al. SUMOylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980.
50. O’Brien K, et al. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585–606.
51. Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–345.
52. Kang M, et al. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021;10(8):e12085.
53. Pua HH, et al. Increased hematopoietic extracellular RNAs and vesicles in the lung during allergic airway responses. Cell Rep. 2019;26(4):933–944.
54. Keller MD, et al. Decoy exosomes provide protection against bacterial toxins. Nature. 2020;579(7898):260–264.
55. Lannigan J, Erdbruegger U. Imaging flow cytometry for the characterization of extracellular vesicles. Methods. 2017;112:55–67.
56. Poggio M, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. *Cell*. 2019;177(2):414–427.
57. Chen G, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*. 2018;560(7718):382–386.
58. Kugeratski FG, Kalluri R. Exosomes as mediators of immune regulation and immunotherapy in cancer. *FEBS J*. 2021;288(1):10–35.
59. Hsin JP, et al. The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. *Nat Immunol*. 2018;19(10):1137–1145.
60. Santangelo L, et al. The RNA-binding protein SYNCRIPT is a component of the hepatocyte exosomal machinery controlling MicroRNA sorting. *Cell Rep*. 2016;17(3):799–808.
61. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. *Nat Immunol*. 2019;20(8):970–979.
62. Khan P, et al. RNA-based therapies: a cog in the wheel of lung cancer defense. *Mol Cancer*. 2021;20(1):54.
63. Penrose HM, et al. Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapy. *Sci Rep*. 2021;11(1):9010.
64. Mikami Y, et al. MicroRNA-221 and -222 modulate intestinal inflammatory Th17 cell response as negative feedback regulators downstream of interleukin-23. *Immunity*. 2021;54(3):514–525.
65. Kowal J, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci U S A*. 2016;113(8):E968–E977.
66. Stephens WZ, et al. Epithelial-myeloid exchange of MHC class II constrains immunity and microbiota composition. *Cell Rep*. 2021;37(5):109916.
67. Chiaro TR, et al. A member of the gut mycobiota modulates host purine metabolism exacerbating colitis in mice. *Sci Transl Med*. 2017;9(380):eaaf9044.
68. Wallace J, et al. Genome-wide CRISPR-Cas9 screen identifies MicroRNAs that regulate myeloid leukemia cell growth. *PLoS One*. 2016;11(4):e0153689.
69. Runtsch MC, et al. Anti-inflammatory microRNA-146a protects mice from diet-induced metabolic disease. *PLoS Genet*. 2019;15(2):e1007970.